NCT04243122View on ClinicalTrials.gov

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

May 3, 2024

Conditions
Myeloproliferative Neoplasm (MPN)Essential Thrombocythemia (ET)JAK2 MutationPolycythemia Vera (PV)Primary MyelofibrosisVenous Thromboembolism (VTE)
Interventions
DRUG

Apixaban 2.5 MG Oral Tablet [ELIQUIS]

2.5mg twice per day for 6 months Then treated \& followed up as per standard of care

DRUG

Aspirin 81 mg

81mg once per day for 6 months Then treated \& followed up as per standard of care

Trial Locations (1)

K1H 8L6

The Ottawa Hospital, Ottawa

Sponsors
All Listed Sponsors
collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

collaborator

the Association médicale universitaire de l'Hôpital Montfort (AMUHM)

UNKNOWN

collaborator

Canadian Hematology Society

UNKNOWN

lead

Ottawa Hospital Research Institute

OTHER